Pharmacological characterization of LPS and opioid interactions at the toll-like receptor 4

British Journal of Pharmacology

Volumn 168, Issue 6, 2013, Pages 1421-1429

  Stevens, Craig W ^a   Aravind, S ^a   Das, S ^a   Davis, R L ^a  

^a OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

fentanyl; FNA; lipopolysaccharide (LPS); morphine; naltrexone; opioid immune crosstalk; opioids; toll like receptor 4 (TLR4)

Indexed keywords

BETA FUNALTREXAMINE; CYTOKINE RECEPTOR ANTAGONIST; FENTANYL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE ANTAGONIST; MORPHINE; NALOXONE; NALTREXONE; OPIATE DERIVATIVE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; CARBOHYDRATE ANALYSIS; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; INTRACELLULAR SIGNALING; MEDIAN EFFECTIVE CONCENTRATION; MONOTHERAPY; NERVOUS SYSTEM INFLAMMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REPORTER CELL;

ANALGESICS, OPIOID; ANTIGENS, CD14; BINDING, COMPETITIVE; DRUG ANTAGONISM; ESCHERICHIA COLI K12; GENES, REPORTER; HEK293 CELLS; HUMANS; KINETICS; LIGANDS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ANTIGEN 96; NARCOTIC ANTAGONISTS; NERVE TISSUE PROTEINS; NF-KAPPA B P50 SUBUNIT; RECEPTORS, OPIOID, MU; RECOMBINANT PROTEINS; RHODOBACTER SPHAEROIDES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84874408845     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12028     Document Type: Article

References (38)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Börner C, Stumm R, Höllt V, Kraus J, (2007). Comparative analysis of mu-opioid receptor expression in immune and neuronal cells. J Neuroimmunol 188: 56-63.
3. Börner C, Höllt V, Kraus J, (2012). Mechanisms of the inhibition of nuclear factor-κB by morphine in neuronal cells. Mol Pharmacol 81: 587-597.
4. Davis RL, Buck DJ, Saffarian N, Stevens CW, (2007). The opioid antagonist, beta-funaltrexamine, inhibits chemokine expression in human astroglial cells. J Neuroimmunol 186: 141-149.
5. Davis RL, Buck DJ, Saffarian N, Mohan S, DeSilva U, Fernando SC, et al. (2008). Beta-funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells. J Neuroimmune Pharmacol 3: 150-153.
6. Deshpande M, Zheng J, Borgmann K, Persidsky R, Wu L, Schellpeper C, et al. (2005). Role of activated astrocytes in neuronal damage: potential links to HIV-1-associated dementia. Neurotox Res 7: 183-192.
7. El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, Knapp PE, et al. (2008). Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca(2+)](i), NF-κB trafficking and transcription. PLoS ONE 3: e4093.
8. Erridge C, (2010). Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol 87: 989-999.
9. Franchi S, Moretti S, Castelli M, Lattuada D, Scavullo C, Panerai AE, et al. (2012). Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages. Brain Behav Immun 26: 480-488.
10. Gavériaux-Ruff C, Filliol D, Simonin F, Matthes HW, Kieffer BL, (2001). Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J Pharmacol Exp Ther 298: 1193-1198.
11. (2+) responses in inflammatory activated astrocytes co-cultured with brain endothelial cells. Neuroscience 155: 1237-1249.
12. He L, Li H, Chen L, Miao J, Jiang Y, Zhang Y, et al. (2011). Toll-like receptor 9 is required for opioid-induced microglia apoptosis. PLoS ONE 6: e18190.
13. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR, (2007). Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci World J 7: 98-111.
14. Hutchinson MR, Zhang Y, Brown K, Coats BD, Shridhar M, Sholar PW, et al. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 28: 20-29.
15. Hutchinson MR, Zhang Y, Shridhar M, Evans JH, Buchanan MM, Zhao TX, et al. (2010a). Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 24: 83-95.
16. Hutchinson MR, Loram LC, Zhang Y, Shridhar M, Rezvani N, Berkelhammer D, et al. (2010b). Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 168: 551-563.
17. Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, et al. (2010c). Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 167: 880-893.
18. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR, (2011). Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 63: 772-810.
19. Jan WC, Chen CH, Hsu K, Tsai PS, Huang CJ, (2011). L-type calcium channels and mu-opioid receptors are involved in mediating the anti-inflammatory effects of naloxone. J Surg Res 167: 263-272.
20. Kenny EF, O'Neill LA, (2008). Signaling adaptors used by Toll-like receptors: an update. Cytokine 43: 342-349.
21. Lewis SS, Hutchinson MR, Rezvani N, Loram LC, Zhang Y, Maier SF, et al. (2010). Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience 165: 569-583.
22. Liu B, Du L, Kong LY, Hudson PM, Wilson BC, Chang RC, et al. (2000a). Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures. Neuroscience 97: 749-756.
23. Liu B, Du L, Hong JS, (2000b). Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 293: 607-617.
24. Liu Y, Qin L, Wilson BC, An L, Hong JS, Liu B, (2002). Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons. J Pharmacol Exp Ther 302: 1212-1219.
25. Loane DJ, Byrnes KR, (2010). Role of microglia in neurotrauma. Neurother 7: 366-377.
26. McCoy MK, Tansey MG, (2008). TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5: 45-58.
27. Ninkovic̈ J, Roy S, (2011). Role of the mu-opioid receptor in opioid modulation of immune function. Amino Acids doi: 10.1007/s00726-011-1163-0
28. O'Neill LA, (2008). The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 226: 10-18.
29. Rogers TJ, Peterson PK, (2003). Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 24: 116-121.
30. Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA, (1998). Morphine modulates NF-κB activation in macrophages. Biochem Biophys Res Commun 245: 392-396.
31. Ruzicka BB, Fox CA, Thompson RC, Meng F, Watson SJ, Akil H, (1995). Primary astroglial cultures derived from several rat brain regions differentially express mu, delta and kappa opioid receptor mRNA. Brain Res Mol Brain Res 34: 209-220.
32. Schild HO, (1947). The use of drug antagonists for the identification and classification of drugs. Br J Pharmacol 2: 251-258.
33. Sethi G, Tergaonkar V, (2009). Potential pharmacological control of the NF-κB pathway. Trends Pharmacol Sci 30: 313-321.
34. Stevens CW, (2009). The evolution of vertebrate opioid receptors. Front Biosci 14: 1247-1269.
35. Stiene-Martin A, Zhou R, Hauser KF, (1998). Regional, developmental, and cell cycle-dependent differences in mu, delta, and kappa-opioid receptor expression among cultured mouse astrocytes. Glia 22: 249-259.
36. Wang X, Loram LC, Ramos K, de, Jesus AJ, Thomas J, Cheng K, et al. (2012). Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A 17: 6325-6330.
37. Watkins LR, Hutchinson MR, Rice KC, Maier SF, (2009). The 'toll' of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30: 581-591.
38. Zhang Y, Li H, Li Y, Sun X, Zhu M, Hanley G, et al. (2011). Essential role of toll-like receptor 2 in morphine-induced microglia activation in mice. Neurosci Lett 489: 43-47.